Atlantic Private Wealth’s CRISPR Therapeutics CRSP Stock Holding History

Atlantic Private Wealth’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$830	Hold	15	–	–	﹤0.01%	252
2026 Q2	$818	Hold	15	–	–	﹤0.01%	247
2026 Q1	$714	Hold	15	–	–	﹤0.01%	256
2025 Q4	$787	Hold	15	–	–	﹤0.01%	276
2025 Q3	$972	Hold	15	–	–	﹤0.01%	229
2025 Q2	$730	Hold	15	–	–	﹤0.01%	229
2025 Q1	$510	Buy	+15	New	+$636	﹤0.01%	204
2024 Q4	–	Sell	-15	Closed	-$704	–	198
2024 Q3	$704	Hold	15	–	–	﹤0.01%	179
2024 Q2	$810	Hold	15	–	–	﹤0.01%	99
2024 Q1	$1.02K	Buy	+15	New	+$1.07K	﹤0.01%	104

Other funds holding CRSP

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return

GSK plc London $497M AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Atlantic Private Wealth's CRSP Position: Q3 2026 in Review

Atlantic Private Wealth held its CRISPR Therapeutics (CRSP) position steady in Q3 2026 at 15 shares worth $830. The position accounts for ﹤0.01% of the portfolio, ranked #252.

Atlantic Private Wealth first reported a position in CRSP in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.02K in Q1 2024. 340 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

Atlantic Private Wealth held 15 shares of CRISPR Therapeutics worth $830 as of Q3 2026.
Atlantic Private Wealth left its CRISPR Therapeutics share count unchanged in Q3 2026.
CRISPR Therapeutics made up ﹤0.01% of Atlantic Private Wealth's portfolio in Q3 2026, its #252 holding.
Atlantic Private Wealth first reported a position in CRISPR Therapeutics in Q1 2024 and has held it in 10 quarters since.
Atlantic Private Wealth's CRISPR Therapeutics position peaked at $1.02K in Q1 2024.
340 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on Atlantic Private Wealth's 13F filing for Q3 2026, filed 9 Nov 2026.